NEW YORK (GenomeWeb News) – Genedata and Bayer Schering Pharma have entered into a multi-year collaboration to develop and use Genedata's Biologics Data Platform at Bayer Schering locations, the companies said today.
Under the agreement, BDP will support biologics data management and analysis at Bayer Schering R&D sites in Europe and the US, which are developing protein-based therapeutics for diseases such as cancer, hemophilia, and multiple sclerosis.
Financial terms of the agreement were not disclosed.
BDP is a shared data-storage and data-exchange platform that can synchronize Bayer Schering's activities from biologics screening through production, the companies said.
Developed for both antibody-based and other protein therapeutics, BDP supports informatics tasks such as library generation, laboratory logistics, and biologics registration and analytics.
"The Biologics Data Platform is an important system for our daily operations as it makes the highly interconnected biologics R&D processes more efficient," Heiner Apeler, director of molecular and antibody biology at Bayer Schering, said in a statement.